Annick Ménétrey

579 total citations
25 papers, 430 citations indexed

About

Annick Ménétrey is a scholar working on Pharmacology, Toxicology and Molecular Biology. According to data from OpenAlex, Annick Ménétrey has authored 25 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 7 papers in Toxicology and 6 papers in Molecular Biology. Recurrent topics in Annick Ménétrey's work include Cannabis and Cannabinoid Research (8 papers), Forensic Toxicology and Drug Analysis (7 papers) and Antimicrobial Resistance in Staphylococcus (4 papers). Annick Ménétrey is often cited by papers focused on Cannabis and Cannabinoid Research (8 papers), Forensic Toxicology and Drug Analysis (7 papers) and Antimicrobial Resistance in Staphylococcus (4 papers). Annick Ménétrey collaborates with scholars based in Switzerland, France and United States. Annick Ménétrey's co-authors include Marc Augsburger, Patrice Mangin, Christian Giroud, Thierry Buclin, M. Appenzeller, Laura E. Rothuizen, Bernard Favrat, Frank Sporkert, C. J. P. Giroud and Valerie Nicolas‐Métral and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Chemistry and Cancer Research.

In The Last Decade

Annick Ménétrey

23 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Annick Ménétrey Switzerland 9 288 182 75 53 50 25 430
Eugene D Hayes United States 9 314 1.1× 137 0.8× 56 0.7× 77 1.5× 99 2.0× 21 489
Sarah K. Himes United States 12 179 0.6× 143 0.8× 73 1.0× 32 0.6× 36 0.7× 15 425
Thomas Briellmann Switzerland 8 191 0.7× 152 0.8× 72 1.0× 47 0.9× 26 0.5× 15 377
Hassan Z. Khiabani Norway 12 170 0.6× 221 1.2× 51 0.7× 37 0.7× 101 2.0× 20 461
E. J. Cone United States 12 335 1.2× 371 2.0× 90 1.2× 144 2.7× 60 1.2× 14 697
MA ElSohly United States 5 237 0.8× 66 0.4× 18 0.2× 52 1.0× 53 1.1× 28 335
James R. Soares United States 14 180 0.6× 234 1.3× 86 1.1× 34 0.6× 22 0.4× 36 539
Dean Fritch United States 10 254 0.9× 399 2.2× 116 1.5× 46 0.9× 58 1.2× 10 569
Matthew McMullin United States 9 205 0.7× 260 1.4× 63 0.8× 60 1.1× 19 0.4× 14 465
Michelle R. Peace United States 16 216 0.8× 217 1.2× 36 0.5× 92 1.7× 24 0.5× 37 726

Countries citing papers authored by Annick Ménétrey

Since Specialization
Citations

This map shows the geographic impact of Annick Ménétrey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annick Ménétrey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annick Ménétrey more than expected).

Fields of papers citing papers by Annick Ménétrey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annick Ménétrey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annick Ménétrey. The network helps show where Annick Ménétrey may publish in the future.

Co-authorship network of co-authors of Annick Ménétrey

This figure shows the co-authorship network connecting the top 25 collaborators of Annick Ménétrey. A scholar is included among the top collaborators of Annick Ménétrey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annick Ménétrey. Annick Ménétrey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jacob, Dominik, Ulrike Gradhand, Christine K. Maurer, et al.. (2025). In vitro-in vivo extrapolation of intrinsic clearance based on data from human hepatocyte spheroids – a case study with the low-clearance drug xevinapant. Xenobiotica. 55(10). 729–736.
2.
Marquardt, Moritz, et al.. (2025). P-65. Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal Antibiotic. Open Forum Infectious Diseases. 12(Supplement_1). 1 indexed citations
3.
Cameron, David R., Christopher M. Rubino, Annick Ménétrey, et al.. (2025). P-1229. Assessment of Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment for the Anti-Staphylococcal Antibiotic Afabicin. Open Forum Infectious Diseases. 12(Supplement_1). 1 indexed citations
4.
Nielsen, Elisabet I., et al.. (2024). Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. 79(12). 3150–3159. 3 indexed citations
5.
Gomez‐Roca, Carlos, Caroline Even, Christophe Le Tourneau, et al.. (2021). Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer. Clinical and Translational Science. 15(1). 55–62. 17 indexed citations
6.
Nicolas‐Métral, Valerie, Anne Vaslin, Jeffrey G. Supko, et al.. (2015). Abstract CT228: Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients. Cancer Research. 75(15_Supplement). CT228–CT228. 3 indexed citations
7.
Chessex, Anne Vaslin, Corinne Moulon, Valerie Nicolas‐Métral, et al.. (2014). 547 Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations. European Journal of Cancer. 50. 177–178. 1 indexed citations
8.
Rouits, Elisabeth, Per Olsson, Bruno Gavillet, et al.. (2014). Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment.. Journal of Clinical Oncology. 32(15_suppl). 2585–2585. 1 indexed citations
9.
Barve, Avantika, Steven J. Kovacs, Annick Ménétrey, et al.. (2014). The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans. Clinical Pharmacology in Drug Development. 4(1). 25–32. 5 indexed citations
10.
Giroud, C., Marc Augsburger, Bernard Favrat, et al.. (2006). Effets du cannabis oral et du dronabinol sur la capacité à conduire. Annales Pharmaceutiques Françaises. 64(3). 161–172. 8 indexed citations
11.
12.
Favrat, Bernard, Annick Ménétrey, Marc Augsburger, et al.. (2005). Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry. 5(1). 17–17. 64 indexed citations
13.
Augsburger, Marc, et al.. (2005). Concentration of drugs in blood of suspected impaired drivers. Forensic Science International. 153(1). 11–15. 80 indexed citations
14.
Giroud, Christian, Chin B. Eap, Marc Augsburger, et al.. (2004). Death following acute poisoning by moclobemide. Forensic Science International. 140(1). 101–107. 8 indexed citations
15.
16.
Ménétrey, Annick. (2004). Cannabis et conduite automobile. IRIS.
17.
Giroud, C. J. P., et al.. (2003). Determination of zaleplon and zolpidem by liquid chromatography–turbo-ionspray mass spectrometry: application to forensic cases. Journal of Chromatography B. 789(1). 131–138. 28 indexed citations
18.
Genné, Daniel, et al.. (2003). Treatment of Secondary Peritonitis: Is a Less Expensive Broad-Spectrum Antibiotic as Effective as a Carbapenem?. Digestive Surgery. 20(5). 415–420. 6 indexed citations
19.
Giroud, Christian, et al.. (2001). Δ9-THC, 11-OH-Δ9-THC and Δ9-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Science International. 123(2-3). 159–164. 89 indexed citations
20.
Giroud, C., et al.. (2000). Hemp tea versus hemp milk: behavioral, physiological effects, blood, urine, saliva and sweat cannabinoids levels following ingestion by two groups of six healthy volunteers. IRIS. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eugene D Hayes Breakdown of academic impact, for papers by Sarah K. Himes Breakdown of academic impact, for papers by Thomas Briellmann Breakdown of academic impact, for papers by Hassan Z. Khiabani Breakdown of academic impact, for papers by E. J. Cone Breakdown of academic impact, for papers by MA ElSohly Breakdown of academic impact, for papers by James R. Soares Breakdown of academic impact, for papers by Dean Fritch Breakdown of academic impact, for papers by Matthew McMullin Breakdown of academic impact, for papers by Michelle R. Peace
Rankless by CCL
2026